Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giuseppe Nardo
Institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
ORCID:
0009-0006-2085-8882
Observed ORCID:
0009-0006-2085-8882
OpenAlex ID:
A5114733646
Synergistic Potential of Antibiotics with Cancer Treatments
2024
·
Giuseppe Nardo
, Pan Pantziarka
, et al.
·
Cancers
·
17
PDF
Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy
2025
·
Marta Brambilla
, Francesca Barbetta
, et al.
·
Clinical Lung Cancer
·
5
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
2026
·
Arsela Prelaj
, Vanja Miskovic
, et al.
·
Nature Medicine
·
4
CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors
2026
·
Giuseppe Nardo
, Francesca Putti
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
Real-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study
2026
·
Silvia Marchesi
, Paolo Ambrosini
, et al.
·
Cancers
Immune Cell Engagers and “Masking Immunotherapy” for Solid Tumors: Focus on Head and Neck Cancers
2026
·
Giuseppe Nardo
, Deborah Lenoci
, et al.
·
Cancers
Show more works
View as search
Works count:
6
Citation count:
27
H-index:
3
I10-index:
1
Year
Topic
Type